Retatrutide: A Research Overview

Retatrutide is one of the most pharmacologically distinctive research peptides currently under active investigation. As the first triple receptor agonist of its kind — simultaneously engaging the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors — it occupies novel territory in metabolic research, producing effects that early clinical research has reported as exceeding those observed with single or dual agonists. This guide is a working reference for laboratory researchers: structure and specifications, the rationale behind triple agonism, key published studies, handling protocols, and quality considerations when sourcing research-grade material.

Quick reference

Property	Value
Drug class	Triple GLP-1 / GIP / glucagon receptor agonist
Molecular formula	C221H343N59O66
Molecular weight	~4731.5 g/mol
CAS number	2381089-83-2
Amino acid length	39 (with C20 fatty diacid modification)
Half-life (research)	~6 days in published pharmacokinetic studies
Form	Lyophilised white to off-white powder
Solubility	Soluble in bacteriostatic water after reconstitution
Storage	−20°C, protected from light and moisture
Developer	Eli Lilly (LY3437943)

Trutide supplies research-grade retatrutide at ≥98% HPLC purity, independently tested by Janoshik Analytical. View product details →

---

Introduction

Retatrutide is a synthetic 39-amino acid linear peptide developed by Eli Lilly as the next pharmacological step beyond dual incretin agonists such as tirzepatide. By engaging three receptors involved in glucose regulation, energy expenditure, and lipid metabolism, retatrutide has produced effects in early-phase clinical research that distinguish it from earlier generations of metabolic peptides.

The compound’s structure is based on a modified glucagon scaffold, with a C20 fatty diacid moiety conjugated to enable extensive albumin binding and a prolonged plasma half-life. Like tirzepatide, this structural feature supports once-weekly subcutaneous dosing in research contexts. Where tirzepatide combines GIP and GLP-1 activity, retatrutide adds a third agonist arm — engagement of the glucagon receptor — which has been hypothesised to increase resting energy expenditure and contribute to lipid metabolism effects observed in published clinical trial data.

This research guide provides a comprehensive reference for laboratory researchers working with retatrutide. It covers the compound’s mechanism of action, the rationale for triple agonism, published research findings, pharmacokinetic profile, handling requirements, and quality considerations relevant to in vitro and preclinical investigation.

---

Mechanism of action

Retatrutide’s pharmacological profile derives from its simultaneous agonist activity at three distinct receptors: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. All three are class B G protein-coupled receptors (GPCRs) and have well-characterised but distinct roles in metabolic regulation.

GLP-1 receptor activation

The glucagon-like peptide-1 receptor is expressed on pancreatic beta cells, in the hypothalamus and brainstem, and across the gastrointestinal tract. Published research on GLP-1 signalling has shown effects on glucose-stimulated insulin secretion, gastric emptying, satiety signalling, and central appetite regulation.

Retatrutide acts as a potent GLP-1 receptor agonist with binding affinity comparable to native GLP-1 in published binding studies. This component of its activity overlaps with established mono-agonists such as semaglutide and dual agonists such as tirzepatide.

GIP receptor activation

The glucose-dependent insulinotropic polypeptide receptor is expressed primarily on pancreatic beta cells, adipocytes, and various tissues involved in energy regulation. GIP receptor activation has been associated in published research with glucose-dependent insulin secretion, modulation of lipid metabolism, and effects on adipocyte function.

Retatrutide’s GIP receptor agonism is structurally inherited from the same design lineage as tirzepatide, producing comparable engagement at this receptor in published binding assays.

Glucagon receptor activation

This is the pharmacologically novel arm of retatrutide’s profile. The glucagon receptor is expressed primarily in the liver, kidney, and adipose tissue. In published research, glucagon receptor activation has been associated with hepatic glucose output, lipid oxidation, and increased resting energy expenditure.

Historically, glucagon agonism would be considered counterproductive in metabolic research because it elevates blood glucose. The retatrutide design rationale is that the simultaneous, dominant GLP-1 activity offsets the glucose-elevating effect of glucagon agonism while preserving the energy expenditure and lipid metabolism benefits. Published research has investigated this balance and reported net glucose-lowering effects despite the glucagon agonist component.

Downstream signalling

All three receptors couple primarily to the Gαs subunit, leading to activation of adenylate cyclase and increased intracellular cyclic adenosine monophosphate (cAMP). However, the tissue distribution of each receptor means the downstream effects diverge — pancreatic effects from GLP-1 and GIP, hepatic and adipose effects from glucagon, central appetite effects from GLP-1.

The combined activation profile produces a metabolic signature that published research has reported as distinct from mono-agonists or dual agonists, with particular interest in the additional contributions of glucagon receptor activity to energy balance parameters.

---

Published research

Retatrutide is a more recently developed compound than tirzepatide, with a smaller but rapidly growing body of peer-reviewed literature. This section summarises key findings available at the time of writing. The compound is currently progressing through phase 3 clinical research and the published evidence base will continue to expand.

Energy balance research

The Phase 2 obesity study published by Jastreboff et al. (2023, New England Journal of Medicine) examined retatrutide’s effects on body weight in research participants without diabetes. Over a 48-week period, dose-dependent reductions in body weight were reported across the 1mg, 4mg, 8mg, and 12mg weekly dosing arms. The published data described body weight changes at the highest dosing levels that exceeded those reported in comparable studies of earlier-generation compounds (Jastreboff et al., 2023, doi:10.1056/NEJMoa2301972).

The TRIUMPH programme of phase 3 clinical trials is currently examining retatrutide across multiple research contexts including obesity (TRIUMPH-1, TRIUMPH-2), type 2 diabetes (TRIUMPH-4), and obesity with knee osteoarthritis (TRIUMPH-3). Topline results from several arms of this programme have been reported, with full peer-reviewed publication ongoing.

Metabolic research

A phase 2 study in research participants with type 2 diabetes published by Rosenstock et al. (2023, The Lancet) reported reductions in HbA1c across multiple dosing levels alongside body weight reductions. The study provided early evidence of retatrutide’s effects on glycaemic parameters in a metabolic disease research context (Rosenstock et al., 2023, doi:10.1016/S0140-6736(23)01053-X).

Hepatic and lipid research

A sub-study examining hepatic effects (Sanyal et al., 2024, Nature Medicine) reported reductions in liver fat content in research participants with metabolic dysfunction-associated steatotic liver disease (MASLD). The published research has been of particular interest because of the role of glucagon receptor agonism in hepatic lipid metabolism, which retatrutide engages directly through its triple agonist profile (Sanyal et al., 2024, doi:10.1038/s41591-024-02878-y).

Pharmacology and receptor characterisation

Beyond clinical efficacy research, retatrutide has been used as a research tool to study triple receptor pharmacology and the contribution of glucagon receptor activation to metabolic outcomes. Research published in journals including Cell Metabolism and JCI Insight has examined the molecular basis of retatrutide’s distinct profile and its place in the broader landscape of incretin and metabolic peptide pharmacology.

---

Pharmacokinetics

The pharmacokinetic profile of retatrutide reflects its design for sustained activity and weekly dosing in research contexts.

Absorption

Following subcutaneous administration in published research, retatrutide reaches maximum plasma concentrations approximately 24 to 72 hours post-administration. The C20 fatty diacid modification produces slow absorption from the injection site, contributing to the compound’s extended duration of action.

Distribution

Retatrutide’s fatty acid modification produces extensive albumin binding (>99%) in published research, which contributes substantially to its prolonged plasma half-life and steady-state distribution profile.

Metabolism

The compound is metabolised via proteolytic cleavage of its peptide backbone, beta-oxidation of the C20 fatty diacid moiety, and amide hydrolysis. Research has not identified specific cytochrome P450 enzymes as major contributors to metabolism, suggesting limited potential for cytochrome-mediated drug-drug interactions in research contexts.

Elimination

The terminal half-life of retatrutide in published pharmacokinetic studies is approximately 6 days, which is slightly longer than tirzepatide’s ~5 day half-life and supports once-weekly dosing protocols in clinical research. Elimination occurs primarily through metabolic clearance.

Dosing in research

Published clinical research has used dose-titration protocols starting at 2mg weekly with increases at 4-week intervals, with maximum dosing levels in published trials reaching 12mg weekly. Researchers should follow their own institutional protocols and study designs when working with the compound.

---

Handling and storage

Proper handling is critical to preserving retatrutide’s integrity and ensuring reproducibility in research applications.

Lyophilised storage

Trutide supplies retatrutide as a lyophilised white to off-white powder in sealed vials. Unopened vials should be stored at −20°C in a dry, dark environment protected from light and moisture. When stored correctly, the lyophilised powder is stable for up to 24-36 months.

Allow vials to equilibrate to room temperature before opening to prevent moisture condensation on the powder, which can compromise stability.

Reconstitution

Retatrutide is reconstituted using sterile bacteriostatic water (BAC water) containing 0.9% benzyl alcohol as a preservative. The benzyl alcohol extends usable life of the reconstituted solution while inhibiting microbial growth.

Standard reconstitution protocol:

1. Allow vials of retatrutide and BAC water to reach room temperature.
2. Add 2-5 mL of BAC water slowly along the side of the vial to achieve the desired concentration (typical research concentrations: 6-15 mg/mL).
3. Gently swirl or tilt the vial until the powder is fully dissolved. Do not shake vigorously, as this can cause foaming or peptide degradation.
4. Once reconstituted, the solution should be clear and colourless to slightly hazy.

For more detail on reconstitution best practice, see our guide on how to reconstitute research peptides.

Reconstituted storage

Once reconstituted, retatrutide solutions should be stored at 2-8°C (refrigerated) and used within 28 days. Do not refreeze reconstituted solutions, as freeze-thaw cycles can compromise peptide integrity.

Handling notes

• Always work in a sterile environment using aseptic technique
• Avoid repeated freeze-thaw cycles with the lyophilised powder
• Protect from direct light and excessive heat during experimental procedures
• Discard any unused solution that becomes cloudy or contains visible particulates
• Follow your laboratory’s standard operating procedures for handling research peptides

For comprehensive guidance on peptide storage protocols, see how to store research peptides correctly.

---

Quality considerations in research

The reliability of research findings using retatrutide depends substantially on the purity and integrity of the compound used. Research-grade material must meet rigorous analytical standards to ensure reproducibility.

Purity verification

Trutide’s retatrutide is independently tested at ≥98% purity minimum by HPLC analysis. Every batch undergoes:

• High-performance liquid chromatography (HPLC) to quantify purity by separating the target peptide from synthesis-related impurities, truncated sequences, and degradation products
• Mass spectrometry to confirm sequence identity by matching the measured molecular weight against the theoretical value

For a fuller explanation of HPLC purity testing methodology, see our guide on understanding peptide purity.

Certificate of Analysis

Every batch of Trutide retatrutide is supplied with a batch-specific Certificate of Analysis (COA) documenting:

• HPLC purity percentage
• Mass spectrometry sequence confirmation
• Batch number and synthesis date
• Independent third-party laboratory verification (Janoshik Analytical)

To learn more about what a COA contains and why it matters, see our guide on what is a Certificate of Analysis.

Why purity matters in receptor pharmacology

Retatrutide’s triple receptor pharmacology makes purity particularly important in research applications. Synthesis-related impurities may include truncated sequences with altered receptor selectivity profiles — for instance, sequences with preserved GLP-1 binding but reduced glucagon receptor engagement. Such impurities could systematically bias receptor pharmacology experiments toward results that don’t reflect the intended compound. For receptor binding studies, in vitro pharmacology, and any quantitative work, ≥98% purity is the accepted research standard.

---

How retatrutide compares to tirzepatide

A common question in metabolic research is how retatrutide differs from tirzepatide, since both compounds are once-weekly injectable peptides with similar structural design and dosing patterns.

The primary difference is receptor coverage: tirzepatide is a dual GIP/GLP-1 agonist, while retatrutide adds the third arm of glucagon receptor agonism. This additional component is hypothesised to contribute to increased resting energy expenditure and direct effects on hepatic lipid metabolism that aren’t engaged by GIP/GLP-1 alone.

The published research available at the time of writing suggests retatrutide produces larger effect sizes than tirzepatide in some research contexts — particularly body weight changes at higher doses — though direct head-to-head comparison studies remain limited.

For the corresponding tirzepatide reference, see our tirzepatide research overview.

---

Frequently asked questions

---

Trutide’s research-grade retatrutide

Trutide supplies research-grade retatrutide to UK-based laboratory researchers:

• 30mg per vial lyophilised powder
• ≥98% HPLC purity independently verified
• Janoshik Analytical third-party testing on every batch
• Batch-specific COA available on request
• Royal Mail Tracked 24 UK dispatch with same-day fulfilment on orders before 2pm
• In stock with consistent supply

View Retatrutide 30mg product page →

You may also need bacteriostatic water for reconstitution.

Research use only. This article is intended for qualified researchers only. All information is provided for educational and scientific reference purposes. Nothing in this article constitutes medical advice. Retatrutide supplied by Trutide is strictly for in vitro laboratory research and is not for human or veterinary use.

---

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. 2023;389:514-526. doi:10.1056/NEJMoa2301972
2. Rosenstock J, Frías JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. The Lancet. 2023;402(10401):529-544. doi:10.1016/S0140-6736(23)01053-X
3. Sanyal AJ, Bedossa P, Fraessdorf M, et al. A phase 2 randomized trial of retatrutide in patients with MASLD. Nature Medicine. 2024. doi:10.1038/s41591-024-02878-y
4. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247.
5. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. The Lancet. 2022;400(10366):1869-1881.

---

Last updated: 14 May 2026